Keeps Pharma Subsidiary, From Insulin to GLP-1... 'Oral Platform' Demonstrates Scalability
- Input
- 2026-10-01 14:46:50
- Updated
- 2026-10-01 14:46:50

[Financial News] Keeps Biopharma is expanding the scope of its oral drug-delivery platform from long-acting to rapid-acting drugs. After converting injectable drugs into oral medications, the company has further advanced its formulation technology to control release rates according to the characteristics of each drug.
Keeps Biopharma said on the 1st that its subsidiary, Keeps Biomed, gave an oral presentation on preclinical findings from an oral insulin study at the European Association for the Study of Diabetes (EASD) conference held in Milan, Italy, on September 30.
Its proprietary oral drug-delivery platform, OraloidTM, encapsulates insulin in ionic nanocomplexes, protects it from gastric acid and digestive enzymes, carries it across the intestinal mucosa, and releases it into the bloodstream. The presentation disclosed pharmacokinetic (PK) indicators, including intestinal absorption, the mechanism of drug protection, and bioavailability.
The company specifically confirmed that it can control the drug-release rate by adjusting the nanoparticles' crystalline form and size, as well as their coating conditions. This expands the platform's scope beyond its existing focus on long-acting formulations to rapid-acting drugs that require relatively fast release.
A bioindustry source explained, "For oral drug-delivery platforms, it is important not merely to increase absorption but also to implement a release profile suited to the characteristics of each drug." The source added, "If the release rate can be controlled, it could help broaden the range of peptide drugs to which the platform can be applied."
Meanwhile, the company also plans to expand the platform's applications beyond insulin to various peptide drugs, including GLP-1.
Yoon Hee-hoon, CEO of Keeps Biomed, added, "We confirmed that the platform can also accommodate drugs requiring different release rates, including rapid-acting drugs. We will broaden its application to various peptide drugs, including GLP-1, and pursue partnerships with multinational pharmaceutical companies."
[email protected] Kim Kyung-a Reporter